Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Orphazyme A/S stock

Own Orphazyme A/S stock in just a few minutes.

Orphazyme A/S is an other business based in the US. Orphazyme A/S shares (ORPH) are listed on the NASDAQ and all prices are listed in US Dollars. Orphazyme A/S employs 141 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Orphazyme A/S

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Orphazyme A/S share price

Use our graph to track the performance of ORPH stocks over time.

Orphazyme A/S shares at a glance

Information last updated 2021-03-10.
52-week range$8.89 - $13.98
50-day moving average $12.71
200-day moving average $11.10
Wall St. target price$21.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Orphazyme A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Orphazyme A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orphazyme A/S financials

Gross profit TTM $0
Return on assets TTM -75.82%
Return on equity TTM -188.05%
Profit margin 0%
Book value N/A
Market capitalisation $421.5 million

TTM: trailing 12 months

Shorting Orphazyme A/S shares

There are currently 11,581 Orphazyme A/S shares held short by investors – that's known as Orphazyme A/S's "short interest". This figure is 56.5% up from 7,400 last month.

There are a few different ways that this level of interest in shorting Orphazyme A/S shares can be evaluated.

Orphazyme A/S's "short interest ratio" (SIR)

Orphazyme A/S's "short interest ratio" (SIR) is the quantity of Orphazyme A/S shares currently shorted divided by the average quantity of Orphazyme A/S shares traded daily (recently around 7193.1677018634). Orphazyme A/S's SIR currently stands at 1.61. In other words for every 100,000 Orphazyme A/S shares traded daily on the market, roughly 1610 shares are currently held short.

To gain some more context, you can compare Orphazyme A/S's short interest ratio against those of similar companies.

However Orphazyme A/S's short interest can also be evaluated against the total number of Orphazyme A/S shares, or, against the total number of tradable Orphazyme A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orphazyme A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Orphazyme A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Orphazyme A/S shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orphazyme A/S.

Find out more about how you can short Orphazyme A/S stock.

Orphazyme A/S share dividends

We're not expecting Orphazyme A/S to pay a dividend over the next 12 months.

Orphazyme A/S share price volatility

Over the last 12 months, Orphazyme A/S's shares have ranged in value from as little as $8.89 up to $13.98. A popular way to gauge a stock's volatility is its "beta".

ORPH.US volatility(beta: 0.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orphazyme A/S's is 0.8501. This would suggest that Orphazyme A/S's shares are less volatile than average (for this exchange).

To put Orphazyme A/S's beta into context you can compare it against those of similar companies.

Orphazyme A/S overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site